The first aim was to retrospectively identify risk factors for the development of early severe preeclampsia (sPE) in patients with obstetric antiphospholipid syndrome (OAPS) who received conventional treatment (CT). The second aim was to evaluate the impact of hydroxychloroquine (HCQ) in preventing early sPE among a subgroup of patients considered at high risk.
Methods
A total of 102 women diagnosed with OAPS and treated with CT since the diagnosis of pregnancy were selected. At the end of pregnancy, we identified risk factors associated with early sPE. According to these risk factors, we collected a new cohort of 42 patients who presented high-risk factors for developing early sPE and split them into two groups according to the treatment received: group A, CT (30 patients); and group B, CT+HCQ (12 patients). We evaluated and compared pregnancy outcomes in both groups.
Results
According to the multivariate analysis, risk factors associated with early sPE and CT were triple positivity for antiphospholipid antibodies (aPL) (OR = 24.70, [4.27–142.92], p < 0.001) and a history of early sPE (OR = 7.11, [1.13–44.64], p = 0.036). A low-risk aPL profile was associated with a good response to CT in preventing early sPE (OR = 0.073, [0.014–0.382], p = 0.002). High-risk patients treated with CT+HCQ had a significantly lower early sPE rate than those treated with CT only (8.3% vs 40.0%; p = 0.03).
Conclusion
Triple positivity for aPL and a history of early sPE are potential strong risk factors for the development of early sPE. HCQ might be an interesting therapeutic option for patients with high-risk factors for early sPE.
LefkouEMamopoulosADagklisTVosnakisCRoussoDGirardiG.Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest2016;
126: 2933–2940.
2.
VogelJPSouzaJPMoriR, et al.; WHO Multicountry Survey on Maternal and Newborn Health Research Network.
Maternal complications and perinatal mortality: findings of the world health organization multicountry survey on maternal and newborn health. BJOG2014;
121(Suppl 1): 76–88.
3.
HeilmannLSchorschMHahnTFareedJ.Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost2011;
37: 141–145.
4.
GibbinsKJTeboAENielsenSKBranchDW.Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study. Lupus2018;
27: 1903–1910.
5.
BartschEMedcalfKEParkALRayJG;
High risk of pre-eclampsia identification G. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and Meta-analysis of large cohort studies. BMJ2016;
353: i1753.
6.
Mayer-PickelKSternCCervar-ZivkovicMSchollWMoertlM.Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. J Reprod Immunol2020;
138: 103101.
7.
ClarkEASilverRMBranchDW.Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?Curr Rheumatol Rep2007;
9: 219–225.
8.
Abou-NassarKCarrierMRamsayTRodgerMA.The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and Meta-analysis. Thromb Res2011;
128: 77–85.
9.
BouvierSCochery-NouvellonELavigne-LissaldeG, et al.
Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood2014;
123: 404–413.
10.
SciasciaSHuntBJTalavera-GarciaELlisoGKhamashtaMACuadradoMJ.The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol2016;
214: e273–e278.
11.
de MoreuilCAlaviZPasquierE.Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. Br J Clin Pharmacol2020;
86: 39–49.
12.
BeliznaCPregnolatoFAbadS, et al.
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev2018;
17: 1153–1168.
13.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
14.
de LarranagaGFForastieroRRCarrerasLOAlonsoBS.Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome. Thromb Res1999;
96: 19–25.
15.
LatinoJOUdrySArandaFMPerés WingeyerSDAFernández RomeroDSde LarrañagaGF.Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus2017;
26: 983–988.
16.
LatinoJOUdrySWingeyerSPRomeroDFMiconePde LarrañagaG.What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?Immunol Res2018;
66: 577–583.
17.
Alijotas-ReigJEsteve-ValverdeEFerrer-OliverasR, et al.; EUROAPS Study Group.
The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev2019;
18: 406–414.
18.
RuffattiASalvanERossTD, et al.
Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost2014;
112: 727–735.
19.
SimchenMJDulitzkiMRofeG, et al.
High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand2011;
90: 1428–1433.
20.
De CarolisSBottaASantucciS, et al.
Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol2010;
38: 116–124.
21.
RuffattiATonelloMCavazzanaABagatellaPPengoV.Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res2009;
123: 482–487.
22.
RuffattiACalligaroADel RossT, et al.
Risk-based secondary prevention of obstetric antiphospholipid syndrome. Lupus2012;
21: 741–743.
23.
De CarolisSTabaccoSRizzoF, et al.
Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmun Rev2018;
17: 956–966.
24.
van HoornMEHagueWMvan PampusMGBezemerDde VriesJIInvestigatorsF.Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol2016;
197: 168–173.
25.
FarquharsonRGQuenbySGreavesM.Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol2002;
100: 408–413.
26.
KuttehWH.Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol1996;
174: 1584–1589.
27.
ArslanEBranchDW.Antiphospholipid syndrome: diagnosis and management in the obstetric patient. Best Pract Res Clin Obstet Gynaecol2020;
64: 31–40.
28.
RuffattiACalligaroAHoxhaA, et al.
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken)2010;
62: 302–307.
29.
SacconeGBerghellaVMaruottiGM, et al.
Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol2017;
216: 525 e521–525 e512.
30.
DuckittKHarringtonD.Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ2005;
330: 565.
31.
VillaPMMarttinenPGillbergJ, et al.
Cluster analysis to estimate the risk of preeclampsia in the high-risk prediction and prevention of preeclampsia and intrauterine growth restriction (PREDO) study. PLoS One2017;
12: e0174399.
32.
RahmanARDeKoninckPMurthiPWallaceEM.Treatment of preeclampsia with hydroxychloroquine: a review. J Matern Fetal Neonatal Med2018;
31: 525–529.
33.
SeoMRChaeJKimYM, et al.
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus2019;
28: 722–730.
34.
DoSCRizkNMDruzinMLSimardJF.Does hydroxychloroquine protect against preeclampsia and preterm delivery in systemic lupus erythematosus pregnancies?Am J Perinatol2020;
37: 873–880.
